Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amniotic mesenchymal stem cell therapy - Amniotics

Next Previous
Drug Profile

Amniotic mesenchymal stem cell therapy - Amniotics

Alternative Names: AmnioPul-02; PulmoStem™

Latest Information Update: 24 Mar 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amniotics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I SARS-CoV-2 acute respiratory disease
  • Preclinical Idiopathic pulmonary fibrosis; Lung disorders

Most Recent Events

  • 09 Feb 2023 Amniotics AB completes a phase I trial in SARS-COV-2 acute respiratory disease (In adults, In the elderly) in Sweden (Parenteral) (NCT05348772)
  • 10 Oct 2022 Phase-I clinical trials in SARS-COV-2 acute respiratory disease (In adults, In the elderly) in Sweden (Parenteral) (NCT05348772)
  • 05 Apr 2022 Amniotics receives approval from Medicines & Healthcare products Regulatory Agency (MHRA) and the Medical Products Agency (MPA) for a phase I/II clinical trial in SARS-CoV-2 acute respiratory disease in the United Kingdom and Sweden

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top